item management s discussion and analysis of financial condition and results of operations repligen is a biopharmaceutical company engaged in the research and development of technologies for drug discovery 
the company also devotes a portion of its resources to proprietary drug discovery projects 
in addition  the company receives income from the sale of products that are manufactured by the company and from its investments 
the company has incurred operating losses since its inception in as of march   its accumulated deficit was  during fiscal  the company completed a major downsizing and restructuring of its activities  including the termination of certain research programs  which significantly reduced its level of operating expenses and its cash burn rate 
these actions were completed in an effort to stabilize repligen s financial condition and preserve its cash resources 
as a result of the reduction of operating expenses and restructuring of its activities  the company believes it has adequate cash reserves at march  to finance its operations at their current levels for at least the next twenty four months 
results of operations fiscal year ended march  compared with fiscal year ended march  revenues 
total revenues for fiscal were  as compared to  in fiscal  a decrease of  research and development revenues for fiscal  totaling  decreased by  or from fiscal levels 
this decrease reflects reduced revenues from its collaborations with eli lilly and company lilly and repligen clinical partners  lp the partnership 
lilly terminated its collaboration and licensing agreement with the company in september  with respect to the joint development of the cdb program 
under the terms of the agreement  the entire cdb program  including preclinical and clinical data packages for product candidates  were returned to the company 
revenues recognized under the lilly agreement totaled  in fiscal the decrease in funding from the partnership reflects a decrease in billings based on the lack of resources of the partnership and the company s termination of its arrangement with the partnership regarding the development and marketing of the rpf program in april research and development revenues recognized under the rpf program totaled  and  in fiscal and fiscal  respectively 
in addition  during fiscal  a one time  fee was paid by genetics institute  inc for the assignment of intellectual property and the transfer of certain reagents associated with the company s immune modulation technology and a one time  license fee was paid by genentech  inc to sublicense the company s patent rights for cda and cd product revenues for fiscal were  compared to  in fiscal the decrease of  or was due to the discontinuance by repligen of contract manufacturing and sales of diagnostic reagents that took place during fiscal year during fiscal year contract service revenues and sales of diagnostic reagents of  were generated by the company 
this reduction was offset by an increase in product sales volume of the company s rprotein a tm and reagent products in fiscal year investment income decreased by  from fiscal levels due primarily to lower average funds available for investment in fiscal other revenues for the fiscal period increased by  from the comparable fiscal period primarily due to the one time sale of equipment and furnishings by the company for  and the one time sale of non investment securities held by the company for approximately  offset by the decrease in management fees received from the partnership 
expenses 
during fiscal  total expenses of  were significantly lower than fiscal expenses of  this decrease resulted from the company s restructuring in during the fourth quarter of fiscal  the company substantially downsized and consolidated its operations in order to stabilize the company s financial condition and preserve its cash reserves 
in fiscal  the company recorded a charge of  to cover severance costs and related benefits  the settlement of equipment and facility lease obligations and the write off of certain leasehold improvements and equipment no longer being utilized  reduced in part by cash received from the sale of assets and the reversal of certain accruals no longer required due to the downsizing 
the total restructuring charge of  included cash related expenditures of  and a non cash charge of  the non cash charge related to the write off of leasehold improvements and equipment no longer being utilized  offset by the reversal of accruals no longer required 
see note of notes to consolidated financial statements 
in may  the company relocated its operations from cambridge  massachusetts to approximately  square feet of subleased office and laboratory space in needham  massachusetts 
this move has resulted in substantial savings in rent and related facility costs 
if the move had been effective as of april   facility related expenses during the year ended march  would have been lower by approximately  research and development expenses for fiscal  totaling  decreased by  or  from fiscal levels 
the decrease in expenses reflects a reduction in research and development headcount and related expenses  decreased development activities  lower expenditures for clinical trials and the company s efforts to reduce costs 
the company anticipates that expenses will remain at the current level until additional research and development funding has been obtained 
cost of goods sold for fiscal decreased by  from the prior fiscal year 
cost of goods sold in fiscal were of product revenues versus of product revenues for fiscal the decrease is the result of a change in product mix between fiscal years and is attributable to lower margins experienced on contract service revenues in fiscal and the result of the realization of inventory in fiscal that had previously been reserved for in fiscal selling  general and administrative expenses for fiscal were  a decrease from fiscal of  this decrease resulted from the reduction of administrative personnel and related expenses as part of the company s cost reduction efforts 
interest expense for fiscal reflects interest incurred by the company through may when its term loan with a bank was paid in full 
in the year ended march   the company acquired  in exchange for the company s common stock  all of the outstanding shares of proscure  inc  a subsidiary of glycan pharmaceuticals  inc glycan 
proscure has licensed the rights to certain drug discovery technologies and lead compounds for application to the field of cancer from glycan  a wholly owned subsidiary of the company 
since the technology acquired will require further development by the company  this acquisition was accounted for as a purchase  with the excess of the purchase price and acquisition costs over the fair valued of the assets acquired  charged to operations of approximately  in the year ended march   the company issued  shares of its common stock for all of the common stock of glycan pharmaceuticals  inc glycan 
the acquisition was accounted for as a purchase  with the excess of the purchase price and acquisition costs over the fair value of the assets acquired of approximately  charged to operations as the cost of acquired research and development 
fiscal year ended march  compared with fiscal year ended march  revenues 
total revenues for fiscal were  as compared to  in fiscal  a decrease of  research and development revenues for fiscal  totaling  decreased by  or from fiscal levels 
this decrease reflects reduced product development funding from lilly with respect to the company s inflammation inhibition cdb program and from the partnership with respect to rpf  offset in part by a  fee paid by genetics institute  inc in september for the assignment of intellectual property and the transfer of certain reagents associated with the company s immune modulation technology and a  license fee paid by genentech  inc in december for the exclusive sublicense to make and sell antibody fragments  engineered peptides and other small molecules that bind to cd and cda 
the decrease in funding from lilly in fiscal was due to the termination of the cdb program 
lilly terminated its collaboration and licensing agreement with the company in september  with respect to the joint development of the cdb program 
under the terms of the agreement  the entire cdb program  including preclinical and clinical data packages for product candidates m and h  were returned to the company 
revenues recognized under the lilly agreement totaled  in fiscal the decrease in funding from the partnership reflects a decrease in billings based on lower levels of research activity and a decrease in the need for process development and manufacturing activity and a lack of resources of the partnership  limiting the partnership s ability to fund the rpf program 
research and development revenues recognized under the rpf program totaled  in fiscal product revenues for fiscal were  compared to  in fiscal the decrease of  or was due to a reduction in product sales volume of the company s rprotein a tm and diagnostic reagent products by  sales of product to hoffmann laroche and abbott laboratories totaling  in fiscal which were not realized in fiscal  offset in part by the recognition of contract service revenues of  generated by the company 
investment income decreased by  from fiscal levels due primarily to lower average funds available for investment in fiscal other revenues for the fiscal period decreased by  from fiscal due primarily to a decrease in management fees received from the partnership 
expenses 
during fiscal  the company substantially downsized and consolidated its operations in order to stabilize the company s financial condition and preserve its cash reserves 
during the fourth quarter  the company recorded a charge of  to cover severance costs and related benefits  the settlement of equipment and facility lease obligations and the write off of certain leasehold improvements and equipment no longer being utilized  reduced in part by cash received from the sale of assets and the reversal of certain accruals no longer required due to the downsizing 
the total restructuring charge of  included cash related expenditures of  and a non cash charge of  the non cash charge related to the write off of leasehold improvements and equipment no longer being utilized  offset by the reversal of accruals no longer required 
see note of notes to consolidated financial statements 
research and development expenses for fiscal  totaling  decreased by  or  from fiscal levels 
the decrease in expenses reflects a reduction in research and development headcount and related expenses  decreased development activities  lower expenditures for clinical trials and the company s efforts to reduce costs 
cost of goods sold for fiscal decreased by  from the prior fiscal year 
cost of goods sold in fiscal were of product revenues versus of product revenues for fiscal the increase in this percentage is the result of a change in product mix between fiscal years and is attributable to lower margins experienced on contract service revenues in fiscal and the write off of products no longer being sold 
selling  general and administrative expenses for fiscal  totaling  increased  from fiscal due primarily to increases in legal expenses and employee retention costs offset in part by a decrease in administrative personnel and related expenses as part of the company s cost reduction efforts 
interest expense for fiscal reflects interest incurred by the company through may when its term loan with a bank was paid in full and the decrease from the comparable fiscal period reflects a full twelve months of interest incurred in fiscal in the year ended march   the company issued  shares of its common stock for all of the common stock of glycan pharmaceuticals  inc glycan 
the acquisition was accounted for as a purchase  with the excess of the purchase price and acquisition costs over the fair value of the assets acquired of approximately  charged to operations as the cost of acquired research and development 
liquidity and capital resources the company s total cash  cash equivalents and marketable securities decreased to  at march  from  at march  this decrease is primarily due to the reductions in payables and accruals of  working capital decreased to  at march  from  at march  capital expenditures for fiscal and were  and  respectively 
the capital expenditures in fiscal primarily reflect the leasehold improvements for the newly leased space and the purchase of research and development equipment 
the company has funded operations primarily with cash derived from the sales of its equity securities  revenue derived from research and development contracts  product sales  investment income and the sale of the company s share of a joint venture 
the company believes it has sufficient cash equivalents and marketable securities to satisfy working capital and capital expenditure requirements for the next twenty four months 
should the company need to secure additional financing to meet its future liquidity requirements  there can be no assurances that the company will be able to secure such financing  or that such financing  if available  will be on terms favorable to the company 
management believes that the company s current operations are not materially impacted by the effects of inflation 

